Update: On September 1, 2020, BRDD revised its Report to correct the “Biosimilars: Market Authorizations” tables.
The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical Drugs Directorate (BRDD; formerly BGTD) and the Natural and Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission Performance Annual Reports for Fiscal Year 2019-2020. The reports contain information regarding pharmaceutical, biologic and radiopharmaceutical, and non-prescription and disinfectant drug submission review activity over five consecutive fiscal years (April 1 to March 31) from 2015-2016 to 2019-2020.
Related Publications & Articles
-
Canada’s Drug Agency releases new resource and data on drug approval and reimbursement pathway
Canada’s Drug Agency (CDA-AMC) published data on Canada’s drug system as part of the Data Systems and Analytics program.Read More -
Health Canada and U.S. FDA agree to establish information sharing program for generic drug submission reviews
Health Canada and the U.S. Food and Drug Administration (FDA) have created a program to support the establishment of a Request for Information Sharing (RIS) program, which will enhance the exchange of...Read More -
Medical Devices updates: Phase II consultation on Medical Devices Regulations amendments, medical device licences guidance and IMDRF table of contents guidance
On November 17, 2025, Health Canada proposed Phase II amendments to the Medical Devices Regulations (MDR). The first phase of amendments came into force on December 14, 2024 and relate to recalls, mod...Read More
